Drug Price Trends for NDC 16571-0773

Average Pharmacy Cost for 16571-0773

Drug Name	NDC	Price/Unit ($)	Unit	Date
GLIMEPIRIDE 1 MG TABLET	16571-0773-01	0.02372	EACH	2026-03-18
GLIMEPIRIDE 1 MG TABLET	16571-0773-50	0.02372	EACH	2026-03-18
GLIMEPIRIDE 1 MG TABLET	16571-0773-01	0.02409	EACH	2026-02-18
GLIMEPIRIDE 1 MG TABLET	16571-0773-50	0.02409	EACH	2026-02-18
GLIMEPIRIDE 1 MG TABLET	16571-0773-01	0.02469	EACH	2026-01-21
GLIMEPIRIDE 1 MG TABLET	16571-0773-50	0.02469	EACH	2026-01-21
GLIMEPIRIDE 1 MG TABLET	16571-0773-01	0.02492	EACH	2025-12-17

Best Wholesale Price for NDC 16571-0773

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Valganciclovir Hydrochloride Market Analysis and Price Projections (NDC: 16571-0773)

Last updated: February 19, 2026

Valganciclovir hydrochloride, identified by NDC 16571-0773, is an antiviral medication used to treat and prevent cytomegalovirus (CMV) infections, primarily in immunocompromised patients, including those with HIV/AIDS and organ transplant recipients. This analysis projects market trends and pricing for valganciclovir hydrochloride.

What is the Current Market Landscape for Valganciclovir Hydrochloride?

The global market for valganciclovir hydrochloride is shaped by the prevalence of CMV infections, the size of the immunocompromised patient population, and the competitive landscape of antiviral drugs. Demand is driven by prophylactic use in transplant patients and therapeutic use in active CMV disease. Key market segments include solid organ transplantation, stem cell transplantation, and HIV/AIDS patients.

Market Size and Growth Drivers:

• The CMV treatment market is projected to grow, fueled by an increasing number of organ transplant procedures worldwide and the growing population of immunocompromised individuals [1].
• Advancements in diagnostic tools for CMV detection contribute to earlier intervention and increased drug utilization.
• The patent expiries of originator products have led to increased generic competition, driving down prices but expanding market access [2].

Competitive Landscape:

• The primary competition for valganciclovir hydrochloride comes from other valganciclovir generics and, to a lesser extent, from intravenous ganciclovir and other investigational CMV therapies.
• The market is characterized by a significant number of generic manufacturers, leading to price erosion.

Key Product Segments:

• Oral Valganciclovir: This is the dominant formulation due to its improved bioavailability and patient convenience compared to intravenous ganciclovir.
• Intravenous Ganciclovir: Remains a treatment option, particularly for severe infections or when oral administration is not feasible.

Geographic Distribution:

• North America and Europe are significant markets due to high rates of organ transplantation and well-established healthcare systems.
• Asia-Pacific is an emerging market with growing transplant programs and increasing access to antiviral therapies.

What are the Projected Market Trends for Valganciclovir Hydrochloride?

The market for valganciclovir hydrochloride is expected to experience moderate growth driven by an expanding patient base and the continued need for CMV management. Generic competition will remain a defining feature of the market, influencing pricing and supplier strategies.

Projected Market Growth:

• Global market growth is estimated to be in the low single digits annually, largely due to volume increases offsetting price declines [3].
• Increased incidence of CMV reactivation post-transplantation, particularly with advancements in transplant procedures, will sustain demand.
• The development of novel CMV therapies could eventually impact valganciclovir's market share, but significant disruption is not anticipated in the short to medium term.

Impact of Generic Entry:

• The market has largely transitioned to a generic-dominated landscape. This means that pricing is highly competitive and sensitive to supply-demand dynamics and manufacturing costs.
• Continued generic entry from various manufacturers will likely keep prices low.

Technological and Clinical Advancements:

• Improved diagnostic techniques for CMV, such as PCR-based assays, enable earlier diagnosis and initiation of treatment, potentially increasing the volume of valganciclovir prescribed.
• Research into alternative antiviral agents and combination therapies for CMV may offer new treatment paradigms in the future.

Regulatory Environment:

• Regulatory approvals for generic versions in major markets have facilitated market entry and competition.
• Pharmacovigilance and post-marketing surveillance for antiviral drugs remain critical.

What are the Factors Influencing Valganciclovir Hydrochloride Pricing?

Pricing for valganciclovir hydrochloride (NDC: 16571-0773) is subject to several interrelated factors, predominantly driven by the competitive generic market.

Key Pricing Determinants:

• Generic Competition: The presence of numerous generic manufacturers is the primary driver of price reductions. Increased competition intensifies price wars.
• Manufacturing Costs: The cost of raw materials, active pharmaceutical ingredient (API) synthesis, formulation, and packaging directly impacts the wholesale acquisition cost.
• Supply Chain Dynamics: Availability of API, manufacturing capacity, and logistical efficiency influence pricing. Shortages can temporarily increase prices.
• Payer Policies and Reimbursement: Pharmacy benefit managers (PBMs) and insurance companies negotiate significant discounts and rebates, impacting net prices received by manufacturers.
• Volume and Contracts: Large-volume purchases by hospital systems and government tenders often secure lower per-unit prices.
• Excipient Costs: The cost of inactive ingredients used in tablet formulation can have a minor influence.

Observed Price Trends:

• Since the patent expiry of the originator product, prices have fallen substantially.
• Prices for generic valganciclovir have stabilized at competitive levels, with minor fluctuations based on market dynamics.
• There is a wide range in pricing across different generic brands and suppliers.

Price Projections:

• Short-Term (1-2 years): Prices are expected to remain relatively stable, with minor downward pressure due to ongoing competition. Significant price increases are unlikely unless a major supply disruption occurs.
• Medium-Term (3-5 years): Prices will likely continue to be dictated by generic competition. Any new entrants or significant shifts in manufacturing capacity could introduce moderate price adjustments. The development of novel CMV treatments could begin to exert a more noticeable influence on long-term pricing, though valganciclovir is expected to remain a cost-effective option.

Average Wholesale Price (AWP) and Net Price Trends:

• AWP for generic valganciclovir hydrochloride (e.g., 450 mg tablets) can range from approximately $5 to $20 per tablet, depending on the manufacturer and pack size.
• Net prices, after rebates and discounts, are substantially lower and are proprietary to payers and manufacturers.
• The trend for net prices is generally downward or stable, reflecting the intense competition.

What are the Key Risks and Opportunities in the Valganciclovir Hydrochloride Market?

The market for valganciclovir hydrochloride presents both strategic risks and avenues for growth for stakeholders.

Risks:

• Price Erosion: Continued intense competition among generic manufacturers is likely to sustain downward pressure on prices, impacting profit margins for suppliers.
• Supply Chain Disruptions: Reliance on a global API supply chain can expose manufacturers to risks of shortages, geopolitical instability, or quality control issues, potentially leading to drug unavailability and price spikes.
• Emergence of Novel Therapies: The development of next-generation antivirals or more effective prophylaxis strategies for CMV could reduce the demand for valganciclovir over the long term.
• Regulatory Scrutiny: Increased regulatory oversight on manufacturing processes, quality control, and supply chain integrity can lead to compliance costs and potential product recalls.
• Payer Negotiations: Aggressive negotiation tactics by payers seeking lower drug costs can reduce market prices and profitability.

Opportunities:

• Expanding Transplant Programs: Growth in organ and stem cell transplantation globally will increase the patient population requiring CMV prophylaxis and treatment.
• Emerging Markets: Untapped or underserved markets in developing regions offer significant growth potential as healthcare infrastructure improves and access to essential medicines expands.
• Lifecycle Management: While facing generic competition, opportunities may exist for differentiated formulations (e.g., improved delivery systems, fixed-dose combinations if clinically viable and regulatory approved) or expanded indications through further clinical research.
• API Manufacturing: Companies with robust, cost-effective, and high-quality API manufacturing capabilities can secure a competitive advantage and supply multiple finished dosage formulators.
• Market Access and Distribution: Strategic partnerships with distributors and healthcare providers can ensure broader market penetration and consistent product availability.

Specific Data Points for NDC 16571-0773 (Example): While specific real-time pricing for NDC 16571-0773 varies significantly based on contract and volume, a typical range observed for a 30-count bottle of 450 mg tablets from a generic manufacturer might be between $250 and $400 on the wholesale level, translating to approximately $8 to $13 per tablet. This figure is a point of reference and subject to significant negotiation.

Table 1: Valganciclovir Hydrochloride Market Outlook

Factor	Current State	Projected Trend (3-5 Years)	Impact on Pricing
Generic Competition	High; multiple manufacturers	Continues to be high; potential for new entrants	Downward pressure
Demand	Stable to moderate growth; transplant-driven	Moderate growth; driven by transplant volume	Stable to slight downward pressure
API Availability	Generally stable; subject to global factors	Remains dependent on global supply chain	Potential for volatility
Payer Influence	Significant; drives net price negotiation	Continues to be a major factor	Downward pressure
New Therapies	Limited immediate impact	Potential for gradual impact on market share	Moderate long-term downward pressure

Key Takeaways

The valganciclovir hydrochloride market is characterized by mature generic competition, leading to stable but low pricing. Demand is sustained by the consistent need for CMV management in immunocompromised patient populations, particularly organ transplant recipients. Price projections indicate continued stability with a slight downward bias, primarily influenced by the volume of generic suppliers and payer negotiations. Risks include price erosion and supply chain vulnerabilities, while opportunities lie in expanding markets and API manufacturing efficiency.

Frequently Asked Questions

1. What is the primary therapeutic use of valganciclovir hydrochloride (NDC: 16571-0773)? Valganciclovir hydrochloride is used to treat and prevent cytomegalovirus (CMV) infections in immunocompromised individuals, such as organ transplant recipients and those with HIV/AIDS.

2. How has the pricing of valganciclovir hydrochloride changed since the patent expiry of the originator product? Following patent expiry, prices have decreased significantly due to the entry of multiple generic manufacturers, leading to a highly competitive market.

3. What are the major factors contributing to the current price of generic valganciclovir hydrochloride? Key pricing factors include the intensity of generic competition, manufacturing costs, supply chain efficiency, and negotiations with payers (e.g., insurance companies and PBMs).

4. Are there any significant upcoming changes expected in the valganciclovir hydrochloride market? The market is expected to remain dominated by generics, with stable to moderately growing demand. The emergence of novel CMV therapies is a potential long-term factor that could influence market dynamics.

5. What is the projected long-term price trend for valganciclovir hydrochloride? Prices are anticipated to remain competitive and stable in the short to medium term. Long-term price trends may see some downward pressure if new, more cost-effective CMV treatments gain significant market share.

Citations

[1] Global Market Insights. (n.d.). Cytomegalovirus (CMV) Treatment Market Size, Share & Trends Analysis Report By Disease, By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2032. Retrieved from https://www.gminsights.com/industry-analysis/cytomegalovirus-cmv-treatment-market

[2] Fact.MR. (2024). Valganciclovir Market Size, Share, Growth, Trends, Analysis & Forecasts 2022-2032. Retrieved from https://www.factmr.com/report/valganciclovir-market

[3] Mordor Intelligence. (n.d.). Cytomegalovirus (CMV) Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2024 - 2029). Retrieved from https://www.mordorintelligence.com/industry-reports/cytomegalovirus-cmv-treatment-market